136 related articles for article (PubMed ID: 34140260)
1. Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas.
El Sayed R; El Darsa H; Kort J; Al Chami F; Ibrahim A; Charafeddine M; Bazarbachi A; Abou Dalle I; El Cheikh J
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):711-719. PubMed ID: 34140260
[TBL] [Abstract][Full Text] [Related]
2. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
3. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
4. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Fitoussi O; Belhadj K; Mounier N; Parrens M; Tilly H; Salles G; Feugier P; Ferme C; Ysebaert L; Gabarre J; Herbrecht R; Janvier M; Van Den Neste E; Morschhauser F; Casasnovas O; Ghesquieres H; Anglaret B; Brechignac S; Haioun C; Gisselbrecht C
Haematologica; 2011 Aug; 96(8):1136-43. PubMed ID: 21546499
[TBL] [Abstract][Full Text] [Related]
5. Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.
Lefrère F; Bastit-Barrau D; Hequet O; Bourin P; Mathieu-Nafissi S; Bohbot A; Tilly H; Salles G; Fermé C; Lapierre V; Fornecker L; Micléa JM; Isebaert L; Bologna S; Fitoussi O; Mounier N; Haioun C
Transfusion; 2013 Jan; 53(1):115-22. PubMed ID: 22563760
[TBL] [Abstract][Full Text] [Related]
6. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.
Haioun C; Mounier N; Emile JF; Ranta D; Coiffier B; Tilly H; Récher C; Fermé C; Gabarre J; Herbrecht R; Morchhauser F; Gisselbrecht C
Ann Oncol; 2009 Dec; 20(12):1985-92. PubMed ID: 19567453
[TBL] [Abstract][Full Text] [Related]
7. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Ketterer N; Coiffier B; Thieblemont C; Fermé C; Brière J; Casasnovas O; Bologna S; Christian B; Connerotte T; Récher C; Bordessoule D; Fruchart C; Delarue R; Bonnet C; Morschhauser F; Anglaret B; Soussain C; Fabiani B; Tilly H; Haioun C
Ann Oncol; 2013 Apr; 24(4):1032-7. PubMed ID: 23235801
[TBL] [Abstract][Full Text] [Related]
8. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
9.
Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.
Camus V; Rossi C; Sesques P; Lequesne J; Tonnelet D; Haioun C; Durot E; Willaume A; Gauthier M; Moles-Moreau MP; Antier C; Lazarovici J; Monjanel H; Bernard S; Tardy M; Besson C; Lebras L; Choquet S; Le Du K; Bonnet C; Bailly S; Damaj G; Laribi K; Maisonneuve H; Houot R; Chauchet A; Jardin F; Traverse-Glehen A; Decazes P; Becker S; Berriolo-Riedinger A; Tilly H
Blood Adv; 2021 Oct; 5(19):3862-3872. PubMed ID: 34461634
[TBL] [Abstract][Full Text] [Related]
11. New developments in the management of diffuse large B-cell lymphoma.
Habermann TM
Hematology; 2012 Apr; 17 Suppl 1():S93-7. PubMed ID: 22507791
[TBL] [Abstract][Full Text] [Related]
12. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
13. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL; Wilson WH; Jung SH; Hsi ED; Maurer MJ; Pederson LD; Polley MC; Pitcher BN; Cheson BD; Kahl BS; Friedberg JW; Staudt LM; Wagner-Johnston ND; Blum KA; Abramson JS; Reddy NM; Winter JN; Chang JE; Gopal AK; Chadburn A; Mathew S; Fisher RI; Richards KL; Schöder H; Zelenetz AD; Leonard JP
J Clin Oncol; 2019 Jul; 37(21):1790-1799. PubMed ID: 30939090
[TBL] [Abstract][Full Text] [Related]
14. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Tilly H; Lepage E; Coiffier B; Blanc M; Herbrecht R; Bosly A; Attal M; Fillet G; Guettier C; Molina TJ; Gisselbrecht C; Reyes F;
Blood; 2003 Dec; 102(13):4284-9. PubMed ID: 12920037
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.
Casasnovas RO; Ysebaert L; Thieblemont C; Bachy E; Feugier P; Delmer A; Tricot S; Gabarre J; Andre M; Fruchart C; Mounier N; Delarue R; Meignan M; Berriolo-Riedinger A; Bardet S; Emile JF; Jais JP; Haioun C; Tilly H; Morschhauser F
Blood; 2017 Sep; 130(11):1315-1326. PubMed ID: 28701367
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
Fohrer C; Caillard S; Koumarianou A; Ellero B; Woehl-Jaeglé ML; Meyer C; Epailly E; Chenard MP; Lioure B; Natarajan-Ame S; Maloisel F; Lutun P; Kessler R; Moulin B; Bergerat JP; Wolf P; Herbrecht R
Br J Haematol; 2006 Sep; 134(6):602-12. PubMed ID: 16889621
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma.
Park S; Jo JC; Do YR; Yang DH; Lim SN; Lee WS; Kim WS; Lee HS; Hong DS; Kim HJ; Shin HJ
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):149-156. PubMed ID: 30581162
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Le Gouill S; Ghesquières H; Oberic L; Morschhauser F; Tilly H; Ribrag V; Lamy T; Thieblemont C; Maisonneuve H; Gressin R; Bouhabdallah K; Haioun C; Damaj G; Fornecker L; Bouhabdallah R; Feugier P; Sibon D; Cartron G; Bonnet C; André M; Chartier L; Ruminy P; Kraeber-Bodéré F; Bodet-Milin C; Berriolo-Riedinger A; Brière J; Jais JP; Molina TJ; Itti E; Casasnovas RO
Blood; 2021 Apr; 137(17):2307-2320. PubMed ID: 33211799
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.
Tilly H; Mounier N; Lederlin P; Brière J; Dupriez B; Sebban C; Bosly A; Biron P; Nouvel C; Herbrecht R; Bordessoule D; Coiffier B
J Clin Oncol; 2000 Mar; 18(6):1309-15. PubMed ID: 10715302
[TBL] [Abstract][Full Text] [Related]
20. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
Rohlfing S; Aurich M; Schöning T; Ho AD; Witzens-Harig M
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):458-63. PubMed ID: 25899891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
